Last reviewed · How we verify
BAY86-5016, SH P00331F
BAY86-5016 is a Factor IIa (thrombin) inhibitor that directly blocks the active site of thrombin to prevent blood clot formation.
BAY86-5016 is a Factor IIa (thrombin) inhibitor that directly blocks the active site of thrombin to prevent blood clot formation. Used for Acute coronary syndrome, Thromboembolism prevention.
At a glance
| Generic name | BAY86-5016, SH P00331F |
|---|---|
| Sponsor | Bayer |
| Drug class | Direct thrombin inhibitor |
| Target | Factor IIa (Thrombin) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
As a direct thrombin inhibitor, BAY86-5016 binds to and inactivates Factor IIa (thrombin), a key serine protease in the coagulation cascade responsible for converting fibrinogen to fibrin and amplifying clot formation. By selectively inhibiting thrombin's catalytic activity, the drug reduces thrombin-mediated platelet activation and fibrin generation, thereby preventing pathological thrombosis while maintaining hemostasis.
Approved indications
- Acute coronary syndrome
- Thromboembolism prevention
Common side effects
- Bleeding
- Dyspepsia
- Nausea
Key clinical trials
- FC Patch Comparator Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |